- This Week in Managed Care: June 14, 2019 (ajmc.com)
Samantha DiGrande, Welcome to This Week in Managed Care from the Managed Markets News Network
- Co-owner, ex-employee of pharmacy in U.S. meningitis outbreak acquitted (reuters.com)
Gregory Conigliaro
A federal judge...tossed the convictions of a co-owner and former employee of a Massachusetts compounding pharmacy accused of conspiring to help it evade regulatory oversight before its drugs caused a deadly 2012 fungal meningitis outbreak...U.S. District Judge Richard Stearns in Boston ruled that New England Compounding Center co-owner Gregory Conigliaro and former employee Sharon Carter did not have fair warning their actions could subject them to prosecution...Jurors convicted Conigliaro and Carter of conspiring to defraud the U.S. Food and Drug Administration by misleading it into thinking NECC was operating like a conventional pharmacy and not like a drug manufacturer...State-regulated compounding pharmacies produce customized drugs pursuant to patient-specific prescriptions to address individual needs. But prosecutors said NECC was actually a drug manufacturer making medications in bulk...READ MORE
- This Week in Managed Care: May 31, 2019 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- Big drug distributor pays $22 million to settle U.S. opioid charges (reuters.com)
Morris & Dickson Co, one of the largest U.S. wholesale drug distributors, agreed to pay $22 million in civil penalties to settle U.S. government charges that it failed to report thousands of suspicious orders of the opioids hydrocodone and oxycodone...The...Louisiana-based company will also spend millions of dollars to hire staff and upgrade oversight to help comply with federal regulations requiring that orders be properly reported...Drug Enforcement Administration...since...2014 uncovered more than 12,000 retail pharmacy orders for hydrocodone and oxycodone that Morris & Dickson should have flagged to that agency...READ MORE
- June 14 Pharmacy Week in Review: Annual OTC Guide Launches with New Pharmacist Recommendations, Study Finds No Benefit of Pretreatment with PDE5i drugs for Patients Receiving LVADs (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- June 7 Pharmacy Week in Review: Early ART May Generate Functional CD8 T-cells in Patients with HIV; ASHP and ADA Meeting Coverage Coming (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- May 31 Pharmacy Week in Review: American Society of Clinical Oncology Meeting Coverage Coming, Behaviors and Psychosocial Stressors May Increase Asthma Risk in Adolescents (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- This Week in Managed Care: June 7, 2019 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- Pharmacy “DIR fee” loophole must close, NACDS RxIMPACT urges (chaindrugreview.com)
The National Association of Chain Drug Stores RxIMPACT program has launched an Action Alert, urging Congress to provide “DIR fee” relief in time to save pharmacies and to reduce seniors’ out-of-pocket drug costs...pharmacy advocates are contacting U.S. Senators and members of the U.S. House of Representatives to build support for the Phair Pricing Act (H.R. 1034/S. 640). The bill would do what a recent Medicare rule left undone: providing relief from abusive pharmacy direct and indirect remuneration fees. The goal is to assure this is part of a drug-pricing bill that is enacted soon...“If our government is serious about stopping this unacceptable treatment of pharmacies, about reducing patients’ drug costs at the pharmacy counter, and about reducing overall healthcare costs, then they need to close this loophole and end the abuses of pharmacy DIR fees now,” said NACDS president and chief executive officer Steven Anderson...READ MORE
- Teva Pharm to pay Oklahoma $85 million to settle opioid claims (reuters.com)Teva reaches $85 million settlement on eve of opioid trial in Oklahoma (statnews.com)
Teva Pharmaceutical Industries Ltd said...it had agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped fuel the U.S. opioid epidemic...Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced...The trial...was set to begin on Tuesday...Oklahoma Attorney General Mike Hunter has alleged that J&J and Teva, along with OxyContin maker Purdue Pharma LP, carried out deceptive marking campaigns that downplayed opioids’ addictive risks while overstating their benefits...READ MORE